Received Sep 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
pulmonary embolisms in both lungs; This is a spontaneous report received from a Consumer or other non HCP from License Party. Other Case identifier(s): AE-020662 (BioNTech). A patient (age and gender not provided) received BNT162b2 (BNT162B2 NOS), in 2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PULMONARY EMBOLISM (medically significant), outcome "unknown", described as "pulmonary embolisms in both lungs". Specifically, the patient shared that she regrets receiving the Pfizer-BioNTech booster in 2022, which she says led to pulmonary embolisms in both lungs. She is now allegedly on lifelong Apixaban blood thinners. She described taking the vaccine as "the biggest regret of my life." Therapeutic measures were taken as a result of pulmonary embolism. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained. BNT162b2 is under agreement with BIONTECH SE.